All In Biotech

Drug Trial Radar · NCT04732416

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

17

Actual

Start

May 5, 2022

Primary completion

Jun 16, 2026

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
Feb 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be administered once weekly in multiple doses to subjects in multiple age including pediatric to find appropriate exposure-response data.

Conditions

  • Congenital Hyperinsulinism

Interventions

  • HM15136Drug

    Low dose of HM15136/ High dose of HM15136, SC injection, weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of incidence of AEs, TEAE, SAE as assessed by CTCAE v5.0Time frame: after multiple subcutaneous (SC) doses of 8 weeks
  2. Number of incidence of clinical laboratory abnormalitiesTime frame: after multiple subcutaneous (SC) doses of 8 weeks
  3. Maximum Serum Concentration [Cmax]Time frame: after multiple subcutaneous (SC) doses of 8 weeks
  4. Time to reach CmaxTime frame: after multiple subcutaneous (SC) doses of 8 weeks

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Otto-von-Guericke-Universitaet Magdeburg

    Magdeburg, Germany

  • Hadassah Medical Center (HMC)

    Jerusalem, Israel

  • Pusan National University Yangsan Hospital

    Pusan, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust

    London, United Kingdom

  • Central Manchester University Hospitals NHS Foundation Trust - Royal Manchester Children's Hospital - Centre for Paediatrics and Child Health

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.